|Chemical and physical data|
|Molar mass||146.25 kg/mol|
|(what is this?)|
Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company.
A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|
Now dropped by Lilly due to lack of efficacy.